201920182017201620152014 March 29, 2019 Summary ToggleSpero Therapeutics Receives FDA Fast Track Designation for SPR994 for the treatment of Complicated Urinary Tract infections and Acute Pyelonephritis March 19, 2019 Summary ToggleSpero Announces Appointment of Cynthia Smith to its Board of Directors March 14, 2019 Summary ToggleSpero Therapeutics Announces Fourth Quarter and Full Year 2018 Operating Results and Provides Pipeline Review March 01, 2019 Summary ToggleSpero Therapeutics to Present at March Investor Conferences February 26, 2019 Summary ToggleSpero Therapeutics Receives QIDP Designation from the U.S. FDA for the Development of SPR720 February 04, 2019 Summary ToggleSpero Therapeutics Announces FDA Acceptance of IND Application for SPR994 January 29, 2019 Summary ToggleSpero Therapeutics Announces Initiation of SPR720 Phase 1 Clinical Trial January 07, 2019 Summary ToggleSpero Therapeutics Signs License Agreement with Everest Medicines to Develop, Manufacture and Commercialize SPR206 in Asia, with Option for SPR741 Rights, and Initiates SPR206 Phase 1 Clinical Trial January 07, 2019 Summary ToggleSpero Therapeutics Announces Positive Feedback from FDA Pre-Phase 3 Meeting for Oral SPR994 and Submission of IND for SPR994 in cUTI November 08, 2018 Summary ToggleSpero Therapeutics Announces Third Quarter 2018 Financial Results and Pipeline Overview Pagination First page First Previous page Previous Page 1 Current page 2 Page 3 Page 4 … Next page Next Last page Last
